enGene (NASDAQ:ENGN) Sees Strong Trading Volume – Still a Buy?

Shares of enGene Holdings Inc. (NASDAQ:ENGN) saw strong trading volume on Wednesday . 416,019 shares were traded during mid-day trading, an increase of 3% from the previous session’s volume of 404,246 shares.The stock last traded at $9.74 and had previously closed at $9.22.

Key Headlines Impacting enGene

Here are the key news stories impacting enGene this week:

• Positive Sentiment: HC Wainwright retains a “Buy” rating and a $25 price target and models a positive FY2030 EPS of $0.61, which supports a bullish long‑term thesis for ENGN. MarketBeat ENGN
• Neutral Sentiment: Short interest data is noisy/uninformative in the latest release (reported as 0 shares and a 0.0 days-to-cover figure), so there’s no clear signal from short sellers right now.
• Neutral Sentiment: Two unrelated automotive stories circulated in feeds (rotary‑engine test and Ford engine issue); they are not material to enGene’s business but may have added noise to sector headlines. China Completes First Test of Rotary Engine Ford Engine Article
• Negative Sentiment: HC Wainwright trimmed practically every near‑term forecast: Q1‑2026 to ($0.65) from ($0.64), Q2‑2026 to ($0.69) from ($0.59), Q3‑2026 to ($0.73) from ($0.63), Q4‑2026 to ($0.78) from ($0.67) and FY‑2026 to ($2.84) from ($2.53). FY‑2027, FY‑2028 and FY‑2029 were also lowered (e.g., FY‑2027 to ($2.60) from ($2.25); FY‑2028 to ($1.60) from ($1.21); FY‑2029 to ($0.83) from ($0.37)). Those downgrades increase short‑term execution and cash‑burn risk, which is a negative catalyst for the stock. MarketBeat ENGN

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ENGN shares. UBS Group lifted their price objective on enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a report on Wednesday, November 12th. Morgan Stanley raised their price target on enGene from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 12th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of enGene in a research report on Wednesday, December 3rd. Raymond James Financial raised enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price objective for the company in a research note on Tuesday, November 11th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of enGene in a research note on Wednesday, November 12th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, enGene presently has a consensus rating of “Moderate Buy” and an average target price of $22.38.

enGene Trading Up 2.4%

The firm has a market cap of $632.72 million, a PE ratio of -4.12 and a beta of -0.28. The firm has a fifty day simple moving average of $7.93 and a two-hundred day simple moving average of $5.88. The company has a current ratio of 6.30, a quick ratio of 10.34 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last announced its earnings results on Monday, December 22nd. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18). Equities analysts forecast that enGene Holdings Inc. will post -1.56 EPS for the current year.

Institutional Investors Weigh In On enGene

Large investors have recently modified their holdings of the stock. Cresset Asset Management LLC purchased a new position in shares of enGene during the second quarter valued at about $36,000. Paloma Partners Management Co bought a new stake in enGene during the 2nd quarter valued at approximately $38,000. PFS Partners LLC purchased a new position in shares of enGene during the 3rd quarter worth approximately $61,000. Raymond James Financial Inc. raised its position in shares of enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares in the last quarter. Finally, Hudson Bay Capital Management LP purchased a new position in shares of enGene in the 3rd quarter valued at approximately $76,000. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.